8 citations
,
October 2017 in “Dermatologic Surgery” Men need higher doses and tailored injection techniques for botulinum toxin treatments due to their unique facial features.
February 2026 in “Oncology Reviews” Sacituzumab tirumotecan shows promise in treating breast cancer with manageable side effects.
March 2017 in “BJU international” The BJUI supports clinical trials as key for unbiased medical evidence and works to enhance their design, reporting, and discussion.
September 2024 in “Journal of the American Academy of Dermatology” Botulinum toxin is not effective or cost-efficient for treating male pattern baldness.
June 2023 in “British Journal of Dermatology” Baricitinib was effective in treating severe and very severe alopecia areata after 52 weeks.
Bilateral Orchiectomy effectively reduces the need for anti-androgen medication in most transgender females.
January 2010 in “Journal of Oriental Medicine” Phellodendri Cortex Extract may help treat enlarged prostate.
6 citations
,
August 2023 in “Behavioural and Cognitive Psychotherapy” Mindfulness-based cognitive therapy may reduce social anxiety and improve wellbeing in people with alopecia areata.
September 2024 in “Journal of Cutaneous and Aesthetic Surgery” Bicalutamide may help treat female pattern hair loss.
11 citations
,
January 1989 Two patients had a unique form of trichothiodystrophy with reduced high-sulfur proteins in their hair.
October 2006 in “Urology” Combination therapy with Finasteride is more effective than alpha-blocker alone for BPH symptoms in small prostate volume.
22 citations
,
March 1999 in “International Journal of Clinical Practice” Diphencyprone (DCP) is an effective treatment for severe alopecia areata and resistant warts, with some risks.
August 2002 in “Inpharma Weekly”
research 22
December 2023 in “Psychiatry Neurology and Medical Psychology” 2 citations
,
October 2020 in “Annals of Oncology” Androgen deprivation therapy might help prevent severe COVID-19, but more research is needed.
33 citations
,
January 2008 in “Journal of Molecular Neuroscience”
8 citations
,
September 2022 in “Human genomics” Key genes and pathways involved in thyroid eye disease were identified, aiding potential treatment and diagnosis.
43 citations
,
August 2010 in “Expert Opinion on Investigational Drugs” Inhibitors of 11β-HSD1 show potential for treating type 2 diabetes but require more testing for safety and effectiveness.
68 citations
,
August 2009 in “American Journal of Medical Genetics Part A” A new classification for trichothiodystrophy helps identify genetic causes and potential treatments.
July 2024 in “Journal of Investigative Dermatology” Pediatric patients with dystrophic epidermolysis bullosa face more hospital admissions, procedures, and complications than others.
April 2005 in “The Journal of urology/The journal of urology” Dutasteride may help treat prostate cancer by causing cancer cells to shrink and die.
Imbalances in metals and proteins may help understand and treat bipolar disorder and schizophrenia.
Men with depression and marijuana usage are more likely to be treated for lower urinary tract symptoms/benign prostatic hyperplasia.
February 2024 in “Journal of the European Academy of Dermatology and Venereology” Baricitinib is effective and safe for long-term use in severe alopecia areata, improving hair regrowth and quality of life with few side effects.
15 citations
,
January 2020 in “BioMed Research International” BTA safely and effectively treats hair loss, and works better with FNS.
6 citations
,
January 2017 in “Dermato-endocrinology” ADT-G may be a useful indicator of increased androgen levels in women with acne and can be lowered with certain birth control pills.
January 2025 in “Current Trends in Pharmacy and Pharmaceutical Chemistry” New methods for measuring dutasteride are effective and reliable.
4 citations
,
May 2025 in “Dermatology and Therapy” Baricitinib effectively improves symptoms of atopic dermatitis and alopecia areata with few side effects.
11 citations
,
December 2002 in “Controlled Clinical Trials” Simple methods using DHT levels effectively assess compliance.
May 2022 in “Reactions Weekly”